

11-19-2008

# Neutralization-Sensitive R5 SHIV-2873Nip Encoding *env* from a Infant with Recent HIV Clade C Infection

Nagadenahalli B. Siddappa  
*Dana-Farber Cancer Institute*

Ruijiang Song  
*Harvard Medical School*

Victor G. Kramer  
*Dana-Farber Cancer Institute*

Agnes-Laurence Chenine  
*Dana-Farber Cancer Institute*

Vijayakumar Velu  
*Division of Microbiology and Immunology, Yerkes National Primate Research Center*

*See next page for additional authors*

Follow this and additional works at: <http://digitalcommons.unl.edu/virologypub>

 Part of the [Virology Commons](#)

---

Siddappa, Nagadenahalli B.; Song, Ruijiang; Kramer, Victor G.; Chenine, Agnes-Laurence; Velu, Vijayakumar; Ong, Helena; Rasmussen, Robert A.; Grisson, Ricky D.; Wood, Charles; Zhang, Hong; Kankasa, Chipepo; Amara, Rama Rao; Else, James G.; Novembre, Francis J.; Montefiori, David; and Ruprecht, Ruth M., "Neutralization-Sensitive R5 SHIV-2873Nip Encoding *env* from a Infant with Recent HIV Clade C Infection" (2008). *Virology Papers*. 141.  
<http://digitalcommons.unl.edu/virologypub/141>

This Article is brought to you for free and open access by the Virology, Nebraska Center for at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Virology Papers by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

---

**Authors**

Nagadenahalli B. Siddappa, Ruijiang Song, Victor G. Kramer, Agnes-Laurence Chenine, Vijayakumar Velu, Helena Ong, Robert A. Rasmussen, Ricky D. Grisson, Charles Wood, Hong Zhang, Chipeco Kankasa, Rama Rao Amara, James G. Else, Francis J. Novembre, David Montefiori, and Ruth M. Ruprecht



1 HIV-C (HIV-C) accounts for >56% of all HIV infections worldwide. To investigate vaccine  
2 safety and efficacy in non-human primates, a pathogenic, R5-tropic, neutralization-  
3 sensitive simian-human immunodeficiency virus (SHIV) encoding HIV-C *env* would be  
4 desirable. We have constructed SHIV-2873Ni, an R5 SHIV encoding a primary pediatric  
5 HIV-C *env* isolated from a 2-month old Zambian infant, who progressed to death within  
6 one year of birth. SHIV-2873Ni was constructed using SHIV-1157ipd3N4 (Song et al., J.  
7 Viol. 80:8729-38, 2006) as backbone since the latter contains additional NF- $\kappa$ B sites in the  
8 long terminal repeats (LTRs) to enhance viral replicative capacity. The parental virus,  
9 SHIV-2873Ni, was serially passaged through 5 rhesus monkeys (RM); SHIV-2873Nip, the  
10 resulting passaged virus, was reisolated from the 4<sup>th</sup> recipient about 1 year post-  
11 inoculation. SHIV-2873Nip was replication-competent in RM peripheral blood  
12 mononuclear cells (PBMC) of all random donors tested, was exclusively R5 tropic and its  
13 *env* gene clustered with HIV-C by phylogenetic analysis; its high sensitivity to  
14 neutralization led to a classification as Tier 1 virus. Indian-origin RM were inoculated by  
15 different mucosal routes, resulting in high peak viral RNA loads. Signs of virus-induced  
16 disease include depletion of gut CD4<sup>+</sup> T lymphocytes, loss of memory T cells in blood, and  
17 thrombocytopenia that resulted in fatal cerebral hemorrhage. SHIV-2873Nip is a highly  
18 replication-competent, mucosally transmissible, pathogenic R5 virus that will be useful to  
19 study viral pathogenesis and to assess the efficacy of immunogens targeting HIV-C Env.

1           Currently, 33 million people are living with HIV/AIDS (www.unaids.org), and the  
2 majority of them live in sub-Saharan Africa, South and Southeast Asia, including China and  
3 India, where HIV subtype C (HIV-C) circulates in >90% of the population (UNAIDS) (50). This  
4 distribution makes HIV-C the most prevalent subtype in the global pandemic, accounting for  
5 >56% of all HIV infections worldwide (www.unaids.org). Globally, HIV is one of the leading  
6 causes of childhood morbidity and mortality. Children account for 20% of all HIV-related  
7 deaths, 7% of individuals living with HIV, and 16% of new infections annually (reviewed in (26,  
8 29, 38). In sub-Saharan Africa, HIV-C is responsible for approximately 50% of all infections,  
9 and a significant number of infections are in infants and children. HIV transmission from  
10 infected mothers to their infants is the primary mode of infection in children and can occur *in*  
11 *utero*, intrapartum, or postnatally through breast milk. The use of antiretroviral drugs has  
12 successfully reduced the rate of HIV infection in infants in the developed world to approximately  
13 1%; nevertheless, such regimens have only recently become available in many of the developing  
14 nations where HIV mother-to-child transmission (MTCT) is most significant (reviewed in (26,  
15 38).

16           Simian-human immunodeficiency viruses (SHIVs) are chimeric viruses that contain HIV  
17 envelope genes in the simian immunodeficiency virus (SIV) backbone. They have been used in a  
18 wide range of studies investigating lentiviral pathogenesis, antiviral immunity, virus-host  
19 interactions, mucosal transmission and vaccine- and drug efficacy (20). However, the majority  
20 of current SHIV strains utilize envelope genes derived from HIV clade B strains, which represent  
21 less than 10% of all global infections. Therefore, the available SHIV chimeras do not reflect the  
22 genetic diversity of the HIV epidemic, which is dominated by non-B clades, especially by HIV-  
23 C. Only a few studies have focused on developing anti-clade C Env vaccines (25, 27, 44, 49)

1 with one efficacy study in primate models (44). To investigate lentiviral pathogenesis as well as  
2 anti-HIV-C vaccine safety and efficacy in non-human primate models, a pathogenic, CCR5-  
3 restricted, clade C SHIV (SHIV-C) would be very useful.

4  
5 Previously, we have generated an R5 SHIV-C, SHIV-1157i (6, 51), which encodes *env*  
6 from a 6-month-old Zambian infant born to an HIV-positive mother. During prospective long-  
7 term follow-up, this infant turned out to be a long-term non-progressor (LTNP) who has  
8 remained asymptomatic at 8 years of age (61). The rhesus monkey (RM)-adapted strain, SHIV-  
9 1157ip, was pathogenic and caused AIDS in several monkeys thus far, but with a relatively slow  
10 rate of disease progression. AIDS developed in RM between 127 – 300 weeks post-inoculation.  
11 A late virus was reisolated and engineered to contain extra NF- $\kappa$ B sites in the long terminal  
12 repeats (LTRs) (51); follow-up times of monkeys infected with this late form are not yet  
13 sufficient to assess development to AIDS, although signs of disease have developed. A possible  
14 explanation is that the *env* gene used to construct the original SHIV-1157i is an important  
15 determinant of the disease progression rate. The fact that the *env* gene was derived from a LTNP  
16 may be linked to the relatively slow disease progression we observed in RM infected with SHIV  
17 encoding the corresponding *env* gene.

18 We sought to test whether constructing an R5 SHIV with an *env* gene derived from a  
19 rapid progressor would give rise to a more virulent R5 SHIV-C. Although HIV- or SIV-infected  
20 individuals with either typical rates of disease progression or with long-term non-progression  
21 have been studied extensively, few reports were focused on the virologic and immunologic  
22 characteristics of patients with rapid disease progression (9, 22). Patients who progress to AIDS  
23 within one to two years from the time of infection have been identified among infants and adults

1 (7, 13, 34, 35, 46), with a higher frequency in infant populations. These patients demonstrate  
2 rapid loss of CD4<sup>+</sup> T cells and lack potent cellular and humoral immune responses.

3 Here we report the construction of SHIV-2873Ni, a chimera that encodes *env* of an R5  
4 HIV-C strain isolated from a rapid progressor, a 2-month-old Zambian baby, who died of AIDS-  
5 related disease within one year of birth. SHIV-2873Ni was serially passaged through 5 RM;  
6 SHIV-2873Nip, the passaged virus, was reisolated and characterized from the 4<sup>th</sup> recipient about  
7 1 year post-inoculation when signs of disease were manifest. The RM-adapted virus caused T-  
8 cell depletion within a few months post-inoculation.

## 11 MATERIALS AND METHODS

13 **Original virus isolates and nomenclature.** HIV2873i is a biological isolate obtained  
14 from a Zambian infant at 2 months of age. The infant, born to an HIV-C-infected mother, was  
15 PCR negative at birth and rapidly progressed to AIDS-related death within one year. The  
16 designation “i” indicates a virus strain (or *env* gene) isolated from an infant. SHIV-2873Ni is the  
17 original, non-adapted infectious molecular clone that contains two NF-κB sites in the 3’ long  
18 terminal repeat (LTR) instead of the usual single NF-kB site present in the SIVmac239 LTR.  
19 This duplicate NF-κB site is copied into the 5’ LTR during subsequent reverse transcription steps  
20 of the retroviral life cycle (8). SHIV-2873Nip, a biological isolate obtained after passage of  
21 SHIV-2873Ni through four RM, was reisolated from a monkey systemically infected for  
22 approximately one year; “p” designates a passaged (or monkey-adapted) virus.

1           **Cell lines, antibodies and viruses.** U87 or GHOST cell lines, which express CD4 only  
2 or CD4 with different chemokine receptors, as well as CEM.NKR.CCR5 cells, were provided by  
3 the NIH AIDS Research & Reference Reagents Program (ARRRP, Germantown, MD).  
4 Neutralizing monoclonal antibodies (nmAbs) 2F5 (36), 2G12 (56) and 4E10 (54) were provided  
5 by Dr. Hermann Katinger (Polymune Scientific, Vienna, Austria). MAb b12 (1) is an IgG1  
6 isotype and was produced by expression in recombinant CHO cells (kindly provided by Dr.  
7 Dennis Burton, Scripps Research Institute, La Jolla, CA). CEMx174-GFP cells, provided by Dr.  
8 Barbara Felber (National Cancer Institute, Frederick, MD), contain the green fluorescent protein  
9 (GFP) gene under HIV-1 LTR regulation and express CXCR4 but not CCR5. TZM-bl cells (also  
10 called JC53-bl [clone 13] cells; ARRRP) (11) are derived from a HeLa cell line (JC.53) that  
11 stably expresses CD4 and CCR5. TZM-bl cells also express luciferase and  $\beta$ -galactosidase under  
12 control of the HIV-1 LTR.

13           **Animals and animal care.** RM (*Macaca mulatta*) of Indian origin were used in this  
14 study. The animals were kept according to National Institutes of Health guidelines on the care  
15 and use of laboratory animals at the Yerkes National Primate Research Center (YNPRC, Emory  
16 University, Atlanta, GA). These facilities are fully accredited by the Association for Assessment  
17 and Accreditation of Laboratory Animal Care International. Animal experiments were approved  
18 by the Animal Care and Use Committees of YNPRC and the Dana-Farber Cancer Institute.

19           **Construction of SHIV-2873Ni molecular clones.** Peripheral blood mononuclear cells  
20 (PBMC) of Zambian infant 2873i were collected two months after it was born to an HIV-positive  
21 mother (62) and briefly cocultured with normal human donor PBMC. DNA from this coculture  
22 was extracted for PCR amplification. A pair of specific primers, designed to amplify the entire  
23 HIV-1 *env*, incorporated the *Hind*III or *Xho*I restriction enzyme sites and had the following



1 sequence: 2873-*HindIII*, 5'-GGGGGAAGCTTATGAGAGTGATGGGGATACAGAGG-3' and  
2 2873-*XhoI*, 5'-CCCCCTCGAGTTATTGCAAAGCTGCTTCAAAGCCC-3'. The full-length  
3 HIV2873i *env* was digested with the restriction enzymes *HindIII* and *XhoI* and cloned into vector  
4 pcDNA6/myc-His B (Invitrogen, Carlsbad, CA). SHIV-1157ipd3N4 (51) encodes *env* of a late  
5 stage SHIV isolated from a RM that developed AIDS 137 weeks after inoculation of SHIV-  
6 1157i. The 2.2 kb *KpnI* (K)-*BamHI* (B) fragment of HIV2873i (spanning most of gp120, the  
7 entire gp41 extracellular domain, the transmembrane region (TM), and a part of the cytoplasmic  
8 domain) was amplified to replace the corresponding region of SHIV-1157ipd3 *env*. The  
9 modified 3'-half was ligated with the 5' half of SHIV-vpu<sup>+</sup> (23) proviral DNA to generate full-  
10 length SHIV-2873Ni (51).

11 **Co-receptor usage of SHIV constructs.** The U87 or GHOST cell lines expressing CD4  
12 alone or CD4 and HIV-1 or SIV coreceptors were used to study virus tropism. U87.CD4,  
13 U87.CD4.CCR1, U87.CD4.CCR2, U87.CD4.CCR3, U87.CD4.CXCR4, U87.CD4.CCR5,  
14 GHOST.BOB and GHOST.BONZO were infected with virus stock. Cells were washed and  
15 resuspended in 1 ml of fresh medium. On days 0, 2, 4, and 6, supernatants were collected for p27  
16 titration. The molecular clones SHIV<sub>SF162P3</sub> (28) (clade B, R5), and SHIV-vpu<sup>+</sup> (23) (clade B,  
17 X4) were used as controls. These experiments were carried out with both SHIV-2873Ni and  
18 SHIV-2873Nip.

19 **Serial passage of SHIV-2873Ni.** Rhesus macaque RBI-9 was inoculated intravenously  
20 (i.v.) with 10 ml of a SHIV-2873Ni stock prepared from RM PBMC. After RBI-9 was  
21 confirmed virus positive by real-time RT-PCR (17), 10 ml of blood from RBI-9 was transferred  
22 i.v. to RAg-9 at week 2 post-inoculation of the donor. Three additional animals, RAi-8, RNt-9  
23 and RGc-9, received serial blood transfers. Animal RWa-9, which had been previously exposed

1 to parental SHIV-2873Ni but had remained uninfected, received blood from donor RAI-8. All  
2 animals were monitored for viral loads, antibody responses, and T-cell subsets.

3 **PCR and sequencing analysis.** Chromosomal DNA was extracted from 10<sup>6</sup> PBMC from  
4 animal RNT-9 using a DNAzol genomic DNA isolation kit (Molecular Research Center Inc.,  
5 Cincinnati, OH). To analyze the molecular evolution of SHIV-2873Nip *env* during in vivo  
6 passage, two different primers were synthesized to amplify the entire *env* gene (approximately  
7 2.5 kb) of SHIV-2873Nip isolated from the last animal RNT-9 about 1 year post-inoculation after  
8 it had developed signs of disease. The *env* gene of SHIV-2873Nip was amplified using the pair  
9 of primers: forward (5'-CCCCAAGCTTCCACCATGAGAGTGAAGGAGAAATATC-3') and  
10 reverse (5'-CCCCGAATTCCATCTTCCTCATCTATATCATCC-3'); the PCR was carried  
11 under end-point dilution conditions. The amplified fragment was cloned into the *HindIII* and  
12 *EcoRI* sites of pcDNA6/myc-His B vector for sequencing. Eight clones encoding an infectious  
13 *env* gene were randomly picked for DNA sequencing.

14 **Phylogenetic analysis.** The sequences of the *env* genes of SHIV-2873Ni, SHIV-  
15 2873Nip, other clade C SHIVs generated by us (SHIV-1157i, SHIV-1157ip, SHIV-  
16 1157ipd3N4) and HIV1084i (14) were aligned with full-length reference sequences of several  
17 Group M viruses obtained from the Los Alamos sequence database  
18 ([http://hiv.lanl.gov/content/hiv-db/SUBTYPE\\_REF/align.html](http://hiv.lanl.gov/content/hiv-db/SUBTYPE_REF/align.html)). Nucleotide sequences were gap-  
19 stripped and aligned using CLUSTAL X (55) and Neighbor-joining trees were generated with  
20 the Kimura 2 parameter substitution model using MEGA3.2 software (21). Pairwise evolutionary  
21 distances were estimated using DNADIST from the PHYLIP 3.6 package (12), and the reliability  
22 of the topologies was evaluated by bootstrap analysis with 100 replicates using DNADIST,  
23 NEIGHBOR and CONSENSE.

1           **Generation of a large-scale SHIV-2873Nip stock.** A large-scale stock of the infectious,  
2 uncloned biological isolate was prepared by infecting concanavalin A (ConA)-stimulated naïve  
3 RM PBMC in the presence of human interleukin-2 (IL-2) (20 U/ml) and tumor necrosis factor  
4 alpha (10 ng/ml) using virus harvested from co-cultured, infected PBMC from monkey RNt-9  
5 approximately 1 year post-inoculation. The rhesus PBMC-grown stock has a p27 concentration  
6 of 140 ng/ml and  $4 \times 10^6$  50% tissue culture infectious doses (TCID<sub>50</sub>) per ml as titrated in TZM-  
7 bl cells according published protocols (11).

8           **Neutralization assays.** The neutralization sensitivity of SHIV-2873Nip was determined  
9 using both PBMC-based and TZM-bl reporter cell line-based neutralization assays, as described  
10 previously (11, 19, 24, 44, 51). In both cases, serial dilutions of either RM sera or mAbs were  
11 set up in triplicate in 96-well plates, virus was added (50-200 TCID<sub>50</sub>) and incubated for 1 h at  
12 37°C. Either PBMC or TZM-bl cells were then added. For assays employing immune sera,  
13 neutralization titers were calculated based on virus production in wells containing sera pooled  
14 from 4 naïve RM as negative controls. In both assays, the concentration of serum giving 50%  
15 neutralization of virus production (IC<sub>50</sub>) was calculated using the level of virus production in  
16 control wells containing the same dilution of pooled naïve sera; for mAb titers, IC<sub>50</sub> was  
17 calculated based on control wells containing virus plus cells only.

18  
19           For the PBMC-based assays, human PBMC were stimulated overnight with PHA (5  
20 µg/ml), washed and added to wells at  $2 \times 10^5$ /well. In assays testing sera, PBMC were washed in  
21 assay plates after 1 day of culture and fresh IL-2 (10 U/ml) - containing media added;  
22 alternatively, in PBMC-based assays testing mAbs, the mAbs were not washed away but were  
23 diluted 1:1 with fresh medium daily, starting on day 3 of the experiment. Because this latter

1 assay condition takes into account the long half-lives of antibodies, neutralization titers may  
2 differ slightly from titers measured by other methods (2, 32). Aliquots of supernatants were  
3 harvested every other day, assayed for p27 levels in wells containing only virus plus cells, and  
4 neutralization activity was measured on the culture day showing linear phase of increase. For  
5 TZM-bl based assays, cells were added in the presence of DEAE dextran (40  $\mu$ g/ml), washed 1x  
6 on day 1, luciferase substrate (Bright-Glo, Promega, Madison, WI) was added on day 2, and  
7 luciferase activity was measured in a luminometer.

8 **Measurement of plasma viral RNA levels.** Plasma viral RNA was isolated by use of the  
9 QiaAmp Viral RNA Mini-Kit (Qiagen), and viral RNA levels were measured by quantitative  
10 reverse-transcriptase polymerase chain reaction (RT-PCR) for SIV *gag* sequences (17) at weeks  
11 0, 1, 2, 4, 8 and monthly thereafter. The assay sensitivity was 50 viral RNA copies/ml.

12 **Oral and intrarectal inoculation of SHIV-2873Nip.** Indian-origin RM received 3 ml or  
13 1 ml of the large-scale virus stock by the oral or intrarectal (i.r.) routes, respectively. Six  
14 additional animals received repeated weekly low-dose i.r. inoculations (up to a maximal number  
15 of 5 inoculations): 1,500 TCID<sub>50</sub> (two monkeys) and 5,000 TCID<sub>50</sub> (four monkeys). Our  
16 protocol stipulated that animals remaining aviremic or failing not reach plasma viral RNA levels  
17 of  $\geq 10^4$  copies/ml at the 2-week time point after the 5<sup>th</sup> low-dose virus exposure would receive a  
18 single high-dose i.r. challenge (30,000 TCID<sub>50</sub>). Blood was collected at 0, 1, 2, 4, 8, and 16  
19 weeks and at 3-month intervals post-inoculation to determine viral RNA loads and to measure T-  
20 cell subsets.

21 **Isolation of cells from blood and rectal biopsies.** PBMC were isolated using standard  
22 procedures; lymphocytes from rectal biopsies were obtained by digestion with collagenase  
23 followed by a separation step using Percoll gradients as described (58). Briefly, 10-20 pinch

1 biopsies were collected in complete RPMI and washed two times with ice-cold Hanks Balanced  
2 Salt Solution (HBSS). Biopsies were digested with collagenase type IV (Worthington,  
3 Lakewood, NJ) and DNase I (Roche, Indianapolis, IN), passed through decreasing size of  
4 needles (16G, 18G and 20G, 5-6 times with each needle), and filtered through a 100  $\mu$ m filter.  
5 Cells were suspended in 35% Percoll in PBS, underlayered with 60% Percoll and centrifuged at  
6 2,500 rpm for 30 min. Cells from the interface were collected, washed and resuspended in  
7 complete RPMI for analysis.

8 **Phenotypic analysis of T cells from blood and rectum.** For T-cell subset analyses,  
9 approximately  $1 \times 10^6$  PBMC or lymphocytes from rectal biopsies were surface stained with the  
10 following mAbs (BD Pharmingen, San Jose, CA): anti-CD3 conjugated to Alexa 700 (clone  
11 SP34-2), anti-CD4 conjugated to PerCp (clone L-200), and anti-CD95 conjugated to APC (clone  
12 DX2). The following mAbs were from eBiosciences (San Diego, CA): anti-CD28 conjugated to  
13 PeCy7 (clone CD28.2), anti-CCR5 conjugated to PE (clone 3A9), and anti-CD45RA (clone  
14 ALB11). Following staining, cells were acquired using LSRII (BD Biosciences, San Jose, CA)  
15 and analyzed using FlowJo software (Treestar, Inc., San Carlos, CA). Lymphocytes were  
16 identified based on scatter pattern and  $CD3^+$ ,  $CD8^-$ ,  $CD4^+$  cells were considered as  $CD4^+$  T cells,  
17 while  $CD3^+$ ,  $CD8^+$ ,  $CD4^-$  cells were considered as  $CD8^+$  T cells.  $CD3^+CD4^+$  T cells were gated  
18 based on CD28 and CD95 expression to define memory  $CD4^+$  T-cell subpopulations: naive  
19 ( $CD28^+CD95^-$ ), central memory ( $CD28^+CD95^+$ ), and effector memory ( $CD28^-CD95^+$ ).

20 **Statistical analysis.** Statistical analysis was performed using Prism® (GraphPad  
21 Software, version 4). Differences in percentages and numbers of lymphocytes were compared  
22 between groups of uninfected versus SHIV-2873Nip-infected animals using the Mann-Whitney  
23 test.



1 2873Ni, contained most of gp120, the entire extracellular domain, the transmembrane region and  
2 part of the cytoplasmic tail of gp41 of the primary isolate HIV2873i.

3 Next, we assessed coreceptor usage of SHIV-2873Ni and SHIV2873Nip; as control, we  
4 also included SHIV-2873i, a virus that encodes the standard SIVmac239 LTRs with only a single  
5 NF- $\kappa$ B site/LTR. These viruses did not replicate in any cell line lacking CCR5, including  
6 CEMx174-GFP, U87.CD4, U87.CD4.CCR1, U87.CD4.CCR2, U87.CD4.CCR3,  
7 U87.CD4.CXCR4, GHOST-BOB and GHOST-BONZO cells (Fig. 2A). We observed productive  
8 infection only in U87.CD4.CCR5 cells (Fig. 2B), suggesting that SHIV-2873Ni exclusively used  
9 CCR5 as coreceptor for entry.

10 **Replication of SHIV-2873Ni in RM PBMC.** We next sought to evaluate the growth of  
11 parental SHIV-2873Ni in PBMC from six randomly selected naïve Indian RM donors. This virus  
12 replicated in PBMC from three donors (RQz, N713, and RCa-3) out of the six naïve donors  
13 tested (data not shown) with peak p27 production in supernatant observed between days 17-21.  
14 These data implied that despite the introduction of extra NF- $\kappa$ B binding sites into the LTRs to  
15 increase viral replicative capacity (51), the new SHIV strain still needed to undergo adaptation  
16 for optimal replication in RM.

17 **Adaptation of SHIV-2873Ni to RM and generation of SHIV-2873Nip.** Rapid animal-  
18 to-animal passage of whole blood at the time of peak viremia (week 2 post-inoculation) was used  
19 to adapt the new SHIV-C strain. This adaptation strategy selects viruses for improved  
20 replication fitness in the new host species without favoring neutralization escape variants since  
21 neutralizing antibody responses typically take many weeks to mature. SHIV-2873Ni was  
22 passaged in five Indian-origin RM (Fig. 3A). The initial cell-free SHIV-2873Ni viral stock was  
23 prepared in rhesus monkey PBMC that were exposed to cell-free supernatant of 293T cells

1 transfected with proviral DNA. The first macaque, RBI-9, was inoculated intravenously with 10  
2 ml of SHIV-2873Ni stock; peak viremia reached  $2.5 \times 10^5$  RNA copies/ml at week 2 post-  
3 inoculation (Fig. 3B). Four additional animals were subjected to serial blood transfer (Fig. 3A),  
4 in which 10 ml of whole blood collected at week 2 post-inoculation was directly transferred into  
5 the following recipients: RAg-9, RAi-8, RWa-9, RNt-9 and RQc-9. Animal RWa-9 had been  
6 previously exposed to supernatant of 293T cells transfected with SHIV-2873Ni proviral DNA,  
7 but had remained uninfected. After receiving infected blood from RM RAi-8, animal RWa-9  
8 became infected as did all monkeys enrolled in the serial virus passage described in Fig. 3A. All  
9 six animals seroconverted (data not shown). The passaged virus reached the highest peak viremia  
10 level in the last recipient, monkey RQc-9. We reisolated a virus about 1 year later from monkey  
11 RNt-9, the penultimate virus recipient in the adaptation schema. This animal was persistently  
12 viremic and had signs of disease progression at that time. The passaged virus, SHIV-2873Nip,  
13 is an uncloned biological isolate that was able to replicate in PBMC of 10 out of 10 RM donors  
14 (data not shown), indicating its adaptation to the new host species, although there was donor-to-  
15 donor variability in virus replication expected for outbred animals.

16 **Phylogenetic analysis.** Primary full-length *env* genes were amplified from genomic  
17 DNA by PCR, cloned into the expression vector pcDNA6/B, and tested for infectivity.  
18 Infectious *env* genes of the various SHIV strains were sequenced and phylogenetic analysis was  
19 performed using Clustal W and Paup. The *env* genes of the newly created SHIV strains clustered  
20 with HIV-C; among the strains tested, the closest relationship was found with our other set of  
21 SHIV-Cs derived from a pediatric HIV-C strain isolated from an infant of the same cohort of  
22 HIV-infected mothers/infants followed prospectively at the University Hospital in Lusaka,  
23 Zambia. Thus, the proximity of the SHIV-2873Nip and SHIV-1157ipd3N4 *env* genes on the



1 phylogenetic tree reflects the closeness of HIV-C strains circulating within the same community  
2 (Fig. 4A). During *env* evolution in the SHIV-infected RM, the genes diverged as expected for  
3 chronically infected hosts (Fig. 4B).

4 **Evolution of SHIV-2873Nip Env during adaptation.** Sequence analysis of SHIV-  
5 2873Nip gp160, cloned from genomic DNA of RNT-9 PBMC collected at about 1 year post-  
6 blood transfer, demonstrated a number of mutations. Compared with the parental Env sequence,  
7 SHIV-2873Ni, the SHIV-2873Nip consensus sequence revealed 14 point mutations throughout  
8 gp160, a 5-amino acid (aa) deletion at the end of V4, as well as a 3 aa deletion at the beginning  
9 of the V5 region (Fig. 4B).

10 **SHIV-2873Nip exclusively uses CCR5 as coreceptor.** We assessed the coreceptor  
11 usage of SHIV-2873Nip as described in Fig. 2B. We observed productive infection only in the  
12 CCR5-expressing cell line suggesting that SHIV-2873Nip maintained R5 tropism after rapid  
13 animal-to-animal passage.

14 **Susceptibility of SHIV-2873Ni and SHIV-2873Nip to neutralization by human**  
15 **nmAbs.** If SHIV-2873Nip is to become a useful tool to assess vaccine efficacy against HIV-C,  
16 maintaining a neutralization-sensitive Env structure will be important for its use as challenge  
17 virus. First, we determined the susceptibility of SHIV-2873Ni and the passaged SHIV-2873Nip  
18 to the broadly reactive human nmAbs IgG1b12, 2G12, 2F5 and 4E10 in human PBMC; the 50  
19 percent inhibitory concentrations (IC<sub>50</sub>) were compared to those of SHIV-1157ipd3N4 (45), an  
20 infectious molecular clade C SHIV clone created by our group earlier. These nmAbs recognize  
21 conserved epitopes on HIV gp120 and on the extracellular domain of gp41. IgG1b12 targets the  
22 CD4 receptor-binding site (63), 2G12 recognizes conserved mannan residues on gp120 (48),

1 whereas 2F5, and 4E10 recognize a coiled-coil region on gp41 that plays a crucial role during  
2 virus fusion with the cell membrane (41, 54, 64, 65).

3 SHIV-2873Ni and SHIV-2873Nip were effectively neutralized by IgG1b12, 2F5 and  
4 4E10, but not by 2G12 (Table 1) in PBMC-based assays. The parental SHIV-2873Ni had a  
5 neutralization profile that was similar to that of SHIV-2873Nip. The IC<sub>50</sub> values for SHIV-  
6 2873Ni and SHIV2873Nip obtained with nmAbs IgG1b12, 2F5 and 4E10 were generally lower  
7 compared to SHIV-1157ipd3N4 (Table 1). Similar results were obtained using RM PBMC in  
8 the neutralization assays. We could not assess the neutralization sensitivity of SHIV-2873Ni in  
9 RM PBMC, since this parental, non-adapted virus did not replicate in the RM donor PBMC pool  
10 tested. Of note, none of the SHIV-Cs tested were susceptible to nmAb 2G12. Its epitope  
11 includes N-linked mannan moieties associated with the five residues N295, N332, N339, N386  
12 and N392, with glycans attached to N295, N332 and N392 contributing to a core epitope (47,  
13 48). Only four of these five residues are present in SHIV-2873Ni and SHIV-2873Nip Env  
14 sequences, and the crucial N295 residue was substituted by T295. The 2G12 epitope has been  
15 found to be missing in many primary HIV-C isolates (24). Compared with the linear motif  
16 NWF<sub>2</sub>DIT recognized by 4E10, two aa (S vs D and S vs T) of this epitope were different in the  
17 predicted SHIV-2873Ni and SHIV-2873Nip Env sequences. In addition, these residues are not  
18 among the crucial residues of this epitope (64). With regards to the linear epitope ELDKWA  
19 recognized by 2F5, ALDSWN was found in both SHIV-2873Ni and SHIV-2873Nip with three  
20 residue substitutions compared to the standard epitope (4). The DSW motif, instead of DKW,  
21 may affect 2F5 binding efficiency.

22 **Susceptibility of SHIV-2873Nip to neutralization by autologous and heterologous**  
23 **RM plasma/sera.** To test the susceptibility of SHIV-2873Nip to neutralization by polyclonal

1 antibodies, we performed a series of PBMC and TZM-bl-based neutralization assays with  
2 autologous and heterologous RM plasma or serum samples. Autologous RM plasma samples  
3 were tested from monkey RNT-9 at the time of virus isolation and 10 months later. Virus was  
4 tested in the presence of plasma from naïve controls and experimental animals; the ratio of the  
5 two values was used to calculate the percent inhibition. SHIV-2873Nip could be neutralized by  
6 autologous plasma (Table 1) and the neutralizing antibody (nAb) titers in the RM increased with  
7 time. Sera from RM chronically infected with an earlier form of SHIV-1157ipd3N4 potently  
8 neutralized SHIV-2873Nip (Table 1, data shown only for 2 RM). Similar results were obtained  
9 using the TZM-bl neutralization assay (data not shown).

10 **Neutralization Tier assignment.** Recently, a Tier system has been developed to  
11 differentiate the neutralization sensitivity of primary HIV or SHIV strains (30). Tier 1 strains are  
12 noticeably neutralization sensitive; Tier 2 strains are more difficult to neutralize and represent  
13 average sensitivity for primary isolates. To assess the neutralization sensitivity, we have tested  
14 SHIV-2873Nip against a panel human nmAbs and polyclonal sera collected from HIV<sup>+</sup>  
15 individuals in TZM-bl cells. According to the data in Table 2, SHIV-2873Nip was classified as  
16 Tier 1 virus and our “late-stage” virus, SHIV-1157ipd3N4, falls into Tier 2. SHIV<sub>SF162P3</sub> and  
17 SHIV<sub>SF162P4</sub>, which had been classified previously as Tier 2 and Tier 1 viruses, respectively,  
18 were used as comparison in the assay.

19 **Mucosal transmissibility of SHIV-2873Nip.** Since approximately 90% of all new HIV  
20 infections are acquired by mucosal exposure during sexual contact or via MTCT, candidate  
21 AIDS vaccines should protect against mucosal virus challenge. Preclinical vaccine safety and  
22 efficacy studies in primate models should thus focus on mucosal virus challenges (reviewed in  
23 (59)). We sought to test whether SHIV-2873Nip could be transmitted mucosally. A large stock

1 of SHIV-2873Nip was generated in RM PBMC. To demonstrate mucosal transmissibility, we  
2 inoculated one monkey each by the oral and i.r. routes. Both animals showed robust viral  
3 replication during the first two weeks of post-inoculation (Fig. 5A). Next, we sought to  
4 determine whether SHIV-2873Nip could lead to systemic infection after repeated weekly low-  
5 dose i.r. challenges; we set 5 weekly inoculations as maximum. Of two RM exposed to a weekly  
6 dose of 1,500 TCID<sub>50</sub>, one animal became viremic after 3 inoculations, whereas the second one  
7 did not and was subsequently given a single dose of 30,000 TCID<sub>50</sub>, which promptly led to high  
8 viremia. Another four RM were challenged weekly with 5,000 TCID<sub>50</sub>; all became viremic after  
9 1 or 4 inoculations, respectively (Fig. 5B). These data indicate that SHIV-2873Nip can be  
10 transmitted reproducibly by mucosal challenge.

11 **Signs of SHIV-2873Nip pathogenicity.** Animal RNt-9, the penultimate recipient during  
12 serial passage, developed thrombocytopenia at 36 weeks post-inoculation; the platelet count  
13 never recovered (Fig. 3C). At 92 weeks post-inoculation, the monkey was found unresponsive  
14 with epistaxis, tachypnea, and an abnormal pulmonary exam by auscultation. At necropsy,  
15 severe multifocal cerebral hemorrhages were noted as well as extensive petechial or multifocal  
16 ecchymotic hemorrhages involving the myocardium, stomach, liver, cecal mucosa, both lungs  
17 and the bladder. The stomach also showed severe ulceration. Clearly, the monkey had  
18 developed a fatal thrombocytopenia. Although the absolute number of peripheral blood CD4<sup>+</sup> T  
19 cells remained normal, the CD4<sup>+</sup>CD29<sup>+</sup> memory T-cell subset was persistently low from 26  
20 weeks post-inoculation onwards (Fig. 3D). Although most lymph nodes were normal at  
21 necropsy, splenomegaly was observed.

22 To assess the effect of SHIV-2873Nip on gut lymphocytes, all six of the mucosally  
23 inoculated RM underwent rectal biopsies between weeks 6 and 12 p.i; animal RNt-9 was

1 subjected to rectal biopsy at week 84 p.i. (eight weeks before the fatal cerebral hemorrhage). We  
2 observed significant depletion of gut CD4<sup>+</sup> T cells in all monkeys compared to uninfected  
3 controls (n = 7; P = 0.0006; Mann-Whitney test, Fig. 5C). In contrast, no statistically significant  
4 differences were noted in the blood (Fig. 5D); thus far, all of the SHIV-2873Nip-infected  
5 monkeys have maintained normal absolute CD4<sup>+</sup> T-cell counts. However, four of the SHIV-  
6 2873Nip-infected animals (RWI-11, RAb-11, RTb-11, RMs-11) demonstrated loss of peripheral  
7 blood CD4<sup>+</sup> memory T cells as assessed by CD4<sup>+</sup>CD29<sup>+</sup> double staining (data not shown).

## 8 9 10 **DISCUSSION**

11  
12 Here, we describe the development of a new R5 SHIV-C that encodes an African  
13 pediatric HIV-C *env*. The newly constructed molecular clone, SHIV-2873Ni, and the biological  
14 isolate, SHIV-2873Nip, have a number of relevant characteristics: 1) SHIV-2873Ni encodes an  
15 HIV-C *env* from a pediatric rapid progressor; 2) SHIV-2873Ni was cloned using the SHIV-  
16 1157ipd3N4 backbone, which has a deletion in the 3' end of HIV *env* that restored the original  
17 SIV *env* C-terminus extending into *nef*; 3) SHIV-2873Ni and its passaged progeny contain extra  
18 NF-κB sites; 4) SHIV-2873Nip retained exclusive R5 tropism; 5) SHIV-2873Nip showed signs  
19 of pathogenicity (memory T-cell depletion, loss of CD4<sup>+</sup> T cells in rectal tissues, and severe,  
20 fatal thrombocytopenia); and 6) SHIV-2873Nip was mucosally transmissible and neutralization  
21 sensitive with a Tier 1 profile.

22 SHIV-2873Nip encodes the envelope gene of a pediatric HIV-C, the most prevalent  
23 strain in the worldwide. Although other SHIV strains (SHIV<sub>CHN19</sub>, SHIV<sub>MJ4</sub>, SHIV-MCGP1.3

1 and SHIV-XJ02170) encoding clade C envelopes have been created, they are either dual-tropic  
2 (SHIV-MCGP1.3) (4), unable to replicate in rhesus macaque PBMC (SHIV<sub>CHN19</sub>) (5), or were  
3 difficult to reisolate post adaptation (SHIV<sub>MJ4</sub> and SHIV-XJ02170) (37, 60). In contrast, SHIV-  
4 2873Nip was mucosally transmissible and was able to replicate vigorously in PBMC of all RM  
5 donors tested, indicating effective adaptation to the new host species. Only one other SHIV-C  
6 strain, SHIV-1157ipd3N4 (51), is exclusively R5 tropic and highly replication-competent in RM.

7 Genetic analysis of SHIV-2873Nip *env* showed a 5-aa deletion in the V4 region, a 3 aa  
8 deletion at the beginning of V5, and fourteen point mutations throughout gp160. Interestingly,  
9 Env was still functional in the pseudotype virus assays *in vitro* despite these deletions. In all  
10 monkeys infected mucosally, SHIV-2873Nip replicated vigorously (peak vRNA levels  $2.1 \times 10^5$   
11 to  $9.5 \times 10^6$  copies/ml). Since most new HIV infections worldwide are acquired mucosally,  
12 mucosal transmission should be employed to assess vaccine efficacy. Clearly, SHIV-2873Nip  
13 showed reproducible mucosal transmissibility.

14 SHIV-2873Nip showed clear signs of pathogenicity within a few months post-  
15 inoculation. Studies with SIV-infected RM and HIV-infected humans have documented that  
16 acute infection is accompanied by a marked depletion of CD4<sup>+</sup> memory T cells, primarily in  
17 mucosal tissues (3, 31, 57). We observed loss of memory CD4<sup>+</sup>CD29<sup>+</sup> T cells in peripheral  
18 blood and depletion of CD4<sup>+</sup> T cells in the gut tissues of all SHIV-2873Nip-infected RM. This  
19 SHIV-C targets memory CD4<sup>+</sup> T cells, whereas the acutely pathogenic, X4- or dual tropic SHIVs  
20 that have been used frequently in vaccine efficacy studies in non-human primate models  
21 predominantly affect naïve CD4<sup>+</sup> T cells (16, 39) and induce precipitous drops in peripheral  
22 blood CD4<sup>+</sup> T cells that are irreversible in most RM (43, 45, 53). In contrast, SHIV-2873Nip  
23 does not induce acute, severe lymphocyte depletion, suggesting that this new R5 SHIV-C

1 exhibits biological characteristics that mimic HIV disease progression in humans. Another R5  
2 SHIV that encodes an HIV clade B *env*, SHIV<sub>SF162P3</sub>, also induces gradual CD4<sup>+</sup> T-cell loss and  
3 causes AIDS in some but not all rhesus macaques (15). Recently, Pahar et al. (40) using  
4 repeated low-dose vaginal SHIV<sub>SF162P3</sub> challenges observed control of viremia in most animals  
5 with modest depletion of the memory CD4<sup>+</sup> T-cell subsets. In our repeated low-dose i.r.  
6 challenge approach, SHIV-2873Nip led to statistically significant depletion of CD4<sup>+</sup> T cells in  
7 the gut.

8 SHIV-2873Nip induced fatal thrombocytopenia in one RM. Thrombocytopenia is a  
9 known complication of lentiviral infection and has been associated with all stages of HIV  
10 infection in humans (reviewed in (18) as well as SIV and SHIV infection in macaques (reviewed  
11 in (17, 33, 51). A relatively recent population-based study examined the association between  
12 AIDS and strokes; a strong link was found with both intracerebral hemorrhages and ischemic  
13 strokes (52). An earlier report described an association between thrombocytopenia and the  
14 development of intracerebral hemorrhages in patients with AIDS (42).

15 Our data indicate that SHIV-2873Nip is sensitive to neutralization by human nmAbs,  
16 polyclonal sera of SHIV-C-infected RM and HIV-C-infected humans as well as HIVIG, which  
17 had been generated from HIV clade B-infected individuals. SHIV-2873Nip was more  
18 neutralization sensitive than SHIV-1157ipd3N4. This is probably due to the fact that we  
19 reisolated SHIV-2873Nip approximately a year after RM RNt-9 became infected. In contrast,  
20 SHIV-1157ipd3N4 was generated from a virus reisolated after a significantly longer period of  
21 time from an infected RM that had progressed to AIDS 2.7 years post-infection; SHIV-  
22 1157ipd3N4 was clearly a neutralization escape virus (51). According to an intriguing study,  
23 recently transmitted HIV-C isolates were surprisingly neutralization sensitive compared to donor

1 virus strains (10, 24). Among discordant couples, newly infected individuals harbored more  
2 neutralization-sensitive viruses compared with the strains that predominated in their infected  
3 partners when tested against contemporaneous donor plasma, suggesting that a bottleneck effect  
4 during or shortly after sexual transmission favored neutralization-sensitive HIV-C quasispecies.  
5 The newly transmitted HIV-C strains had significantly fewer N-linked glycosylation sites and  
6 shorter variable loops compared to the strains that predominated in the infected source persons  
7 (10, 24).

8 Of note, SHIV-2873Nip was classified as a Tier 1 virus based upon its susceptibility to  
9 neutralization by polyclonal sera collected from HIV-C-infected individuals, HIVIG and nmAbs;  
10 this high neutralization sensitivity will be useful in the development of nAb-response-based  
11 AIDS vaccine concepts. To date, the induction of sufficient nAb levels with extended breadth  
12 has been a major hurdle. We suggest that initial vaccine efficacy testing should make use of a  
13 Tier 1 SHIV challenge virus in primate models. If protection is achieved, subsequent vaccine  
14 development steps could then use progressively more difficult-to-neutralize SHIV strains in  
15 primates. SHIV-2873Nip will be useful tool to evaluate vaccine candidates that seek to induce  
16 anti-HIV-C nAb responses, and as of today, it is the only SHIV-C Tier 1 virus described.

17 Our in vivo data indicate that SHIV-2873Nip is a highly replication-competent R5 SHIV-  
18 C. We have previously generated SHIV-1157ipd3N4, a Tier 2 R5 SHIV-C that is pathogenic and  
19 induces AIDS (51), although disease progression has been slow. Nevertheless, SHIV-  
20 1157ipd3N4 has been used successfully to assess the efficacy of a multigenic DNA prime/protein  
21 boost and a multigenic protein-only vaccine (44). The following parameters have been used as  
22 read-outs of vaccine efficacy: complete protection from systemic viral infection, as well as delay  
23 and lowering of peak viremia. We posit that the same strategy can be applied to challenge



1 studies involving the Tier 1 SHIV-2873Nip. In addition, protection from depletion of gut CD4<sup>+</sup>  
2 lymphocytes could serve as measurement of vaccine efficacy. Prolonged, prospective follow-up  
3 will reveal whether SHIV-2873Nip is more pathogenic than SHIV-1157ipd3N4.

4 In summary, the R5 SHIV-2873Nip is a highly replication-competent, mucosally  
5 transmissible Tier 1 SHIV-C that will be a useful tool to study viral pathogenesis and to assess  
6 the efficacy of immunogens targeting HIV-C Env and testing of vaccine candidates that seek to  
7 induce anti-HIV-C nAb responses.

#### 8 9 **ACKNOWLEDGMENTS**

10 We thank Dr. Hermann Katinger (Polymune Scientific, Vienna, Austria) for nmAbs 2G12, 2F5  
11 and 4E10, Dr. Dennis Burton (Scripps Research Institute, La Jolla, CA) for CHO cells  
12 expressing IgG1b12, Dr. Barbara Felber (National Cancer Institute, Frederick, MD) for  
13 CEMx174-GFP cells, Susan Sharp for assistance in the preparation of this manuscript, Dr.  
14 Daniel Anderson for pathology support and Stephanie Ehnert for coordinating sample  
15 collections. We thank Tom Graf and Klemens Wassermann for help with the phylogenetic  
16 analysis. This work was supported by National Institutes of Health grants R01 DE012937, R01  
17 DE016013, and R37 AI034266 to R.M.R., HD39620, TW01429 and RR15635 to C.W., and P01  
18 AI048240 to R.M.R., C.W., R.A.R., and R.D.G., Contract AI30034 to D.C.M., and base grant  
19 RR-00165 providing support to the Yerkes National Primate Research Center.

20

21

22

## References

1. Barbas, C. F., 3rd, E. Bjorling, F. Chiodi, N. Dunlop, D. Cababa, T. M. Jones, S. L. Zebedee, M. A. Persson, P. L. Nara, E. Norrby, and et al. 1992. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. *Proc Natl Acad Sci U S A* 89:9339-43.
2. Binley, J. M., T. Wrin, B. Korber, M. B. Zwick, M. Wang, C. Chappey, G. Stiegler, R. Kunert, S. Zolla-Pazner, H. Katinger, C. J. Petropoulos, and D. R. Burton. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. *J Virol* 78:13232-52.
3. Brenchley, J. M., T. W. Schacker, L. E. Ruff, D. A. Price, J. H. Taylor, G. J. Beilman, P. L. Nguyen, A. Khoruts, M. Larson, A. T. Haase, and D. C. Douek. 2004. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. *J Exp Med* 200:749-59.
4. Cayabyab, M., D. Rohne, G. Pollakis, C. Mische, T. Messele, A. Abebe, B. Etemad-Moghadam, P. Yang, S. Henson, M. Axthelm, J. Goudsmit, N. L. Letvin, and J. Sodroski. 2004. Rapid CD4+ T-lymphocyte depletion in rhesus monkeys infected with a simian-human immunodeficiency virus expressing the envelope glycoproteins of a primary dual-tropic Ethiopian Clade C HIV type 1 isolate. *AIDS Res Hum Retroviruses* 20:27-40.
5. Chen, Z., Y. Huang, X. Zhao, E. Skulsky, D. Lin, J. Ip, A. Gettie, and D. D. Ho. 2000. Enhanced infectivity of an R5-tropic simian/human immunodeficiency virus carrying human immunodeficiency virus type 1 subtype C envelope after serial passages in pig-tailed macaques (*Macaca nemestrina*). *J Virol* 74:6501-10.
6. Chenine, A. L., K. A. Buckley, P. L. Li, R. A. Rasmussen, H. Ong, S. Jiang, T. Wang, P. Augustini, W. E. Secor, and R. M. Ruprecht. 2005. *Schistosoma mansoni* infection promotes SHIV clade C replication in rhesus macaques. *Aids* 19:1793-7.
7. Chiappini, E., L. Galli, P. A. Tovo, C. Gabiano, G. C. Gattinara, A. Guarino, R. Badolato, C. Giaquinto, C. Lisi, and M. de Martino. 2006. Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection. *Aids* 20:207-15.
8. Coffin, J. M., S. H. Hughes, and H. E. Varmus. 1997. *Retroviruses*. Cold Spring Harbor Laboratory Press.
9. Demarest, J. F., N. Jack, F. R. Cleghorn, M. L. Greenberg, T. L. Hoffman, J. S. Ottinger, L. Fantry, J. Edwards, T. R. O'Brien, K. Cao, B. Mahabir, W. A. Blattner, C. Bartholomew, and K. J. Weinhold. 2001. Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression. *AIDS Res Hum Retroviruses* 17:1333-44.
10. Derdeyn, C. A., J. M. Decker, F. Bibollet-Ruche, J. L. Mokili, M. Muldoon, S. A. Denham, M. L. Heil, F. Kasolo, R. Musonda, B. H. Hahn, G. M. Shaw, B. T. Korber, S. Allen, and E. Hunter. 2004. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. *Science* 303:2019-22.
11. Derdeyn, C. A., J. M. Decker, J. N. Sfakianos, X. Wu, W. A. O'Brien, L. Ratner, J. C. Kappes, G. M. Shaw, and E. Hunter. 2000. Sensitivity of human

- 1 immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by  
2 coreceptor specificity defined by the V3 loop of gp120. *J Virol* 74:8358-67.
- 3 12. Felsenstein, J. 1996. Inferring phylogenies from protein sequences by parsimony,  
4 distance, and likelihood methods. *Methods Enzymol* 266:418-27.
- 5 13. Garland, F. C., C. F. Garland, E. D. Gorham, and S. K. Brodine. 1996. Western blot  
6 banding patterns of HIV rapid progressors in the U.S. Navy Seropositive Cohort:  
7 implications for vaccine development. Navy Retroviral Working Group. *Ann*  
8 *Epidemiol* 6:341-7.
- 9 14. Grisson, R. D., A. L. Chenine, L. Y. Yeh, J. He, C. Wood, G. J. Bhat, W. Xu, C.  
10 Kankasa, and R. M. Ruprecht. 2004. Infectious molecular clone of a recently  
11 transmitted pediatric human immunodeficiency virus clade C isolate from Africa:  
12 evidence of intraclade recombination. *J Virol* 78:14066-9.
- 13 15. Harouse, J. M., A. Gettie, T. Eshetu, R. C. Tan, R. Bohm, J. Blanchard, G. Baskin,  
14 and C. Cheng-Mayer. 2001. Mucosal transmission and induction of simian AIDS by  
15 CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). *J Virol*  
16 75:1990-5.
- 17 16. Harouse, J. M., A. Gettie, R. C. Tan, J. Blanchard, and C. Cheng-Mayer. 1999.  
18 Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4  
19 utilizing SHIVs. *Science* 284:816-9.
- 20 17. Hofmann-Lehmann, R., R. K. Swenerton, V. Liska, C. M. Leutenegger, H. Lutz, H.  
21 M. McClure, and R. M. Ruprecht. 2000. Sensitive and robust one-tube real-time  
22 reverse transcriptase-polymerase chain reaction to quantify SIV RNA load:  
23 comparison of one- versus two-enzyme systems. *AIDS Res Hum Retroviruses*  
24 16:1247-57.
- 25 18. Karpatkin, S., M. Nardi, and D. Green. 2002. Platelet and coagulation defects  
26 associated with HIV-1-infection. *Thromb Haemost* 88:389-401.
- 27 19. Kitabwalla, M., F. Ferrantelli, T. Wang, A. Chalmers, H. Katinger, G. Stiegler, L.  
28 A. Cavacini, T. C. Chou, and R. M. Ruprecht. 2003. Primary African HIV clade A  
29 and D isolates: effective cross-clade neutralization with a quadruple combination of  
30 human monoclonal antibodies raised against clade B. *AIDS Res Hum Retroviruses*  
31 19:125-31.
- 32 20. Kramer, V. G., N. B. Siddappa, and R. M. Ruprecht. 2007. Passive immunization as  
33 tool to identify protective HIV-1 Env epitopes. *Curr HIV Res* 5:642-55.
- 34 21. Kumar, S., K. Tamura, and M. Nei. 2004. MEGA3: Integrated software for  
35 Molecular Evolutionary Genetics Analysis and sequence alignment. *Brief Bioinform*  
36 5:150-63.
- 37 22. Kuwata, T., H. Dehghani, C. R. Brown, R. Plishka, A. Buckler-White, T. Igarashi, J.  
38 Mattapallil, M. Roederer, and V. M. Hirsch. 2006. Infectious molecular clones from  
39 a simian immunodeficiency virus-infected rapid-progressor (RP) macaque: evidence  
40 of differential selection of RP-specific envelope mutations in vitro and in vivo. *J*  
41 *Virol* 80:1463-75.
- 42 23. Li, J. T., M. Halloran, C. I. Lord, A. Watson, J. Ranchalis, M. Fung, N. L. Letvin,  
43 and J. G. Sodroski. 1995. Persistent infection of macaques with simian-human  
44 immunodeficiency viruses. *J Virol* 69:7061-7.
- 45 24. Li, M., J. F. Salazar-Gonzalez, C. A. Derdeyn, L. Morris, C. Williamson, J. E.  
46 Robinson, J. M. Decker, Y. Li, M. G. Salazar, V. R. Polonis, K. Mlisana, S. A.

- 1 Karim, K. Hong, K. M. Greene, M. Bilska, J. Zhou, S. Allen, E. Chomba, J.  
2 Mulenga, C. Vwalika, F. Gao, M. Zhang, B. T. Korber, E. Hunter, B. H. Hahn, and  
3 D. C. Montefiori. 2006. Genetic and neutralization properties of subtype C human  
4 immunodeficiency virus type 1 molecular env clones from acute and early  
5 heterosexually acquired infections in Southern Africa. *J Virol* 80:11776-90.
- 6 25. Lian, Y., I. Srivastava, V. R. Gomez-Roman, J. Zur Megede, Y. Sun, E. Kan, S. Hilt,  
7 S. Engelbrecht, S. Himathongkham, P. A. Luciw, G. Otten, J. B. Ulmer, J. J.  
8 Donnelly, D. Rabussay, D. Montefiori, E. J. van Rensburg, and S. W. Barnett. 2005.  
9 Evaluation of envelope vaccines derived from the South African subtype C human  
10 immunodeficiency virus type 1 TV1 strain. *J Virol* 79:13338-49.
- 11 26. Little, K., C. Thorne, C. Luo, M. Bunders, N. Ngongo, P. McDermott, and M. L.  
12 Newell. 2007. Disease progression in children with vertically-acquired HIV infection  
13 in sub-Saharan Africa: reviewing the need for HIV treatment. *Curr HIV Res* 5:139-  
14 53.
- 15 27. Lockey, T. D., K. S. Slobod, T. E. Caver, S. D'Costa, R. J. Owens, H. M. McClure,  
16 R. W. Compans, and J. L. Hurwitz. 2000. Multi-envelope HIV vaccine safety and  
17 immunogenicity in small animals and chimpanzees. *Immunol Res* 21:7-21.
- 18 28. Luciw, P. A., E. Pratt-Lowe, K. E. Shaw, J. A. Levy, and C. Cheng-Mayer. 1995.  
19 Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-  
20 tropic clones of simian/human immunodeficiency viruses (SHIV). *Proc Natl Acad*  
21 *Sci U S A* 92:7490-4.
- 22 29. Luzuriaga, K., and J. L. Sullivan. 2002. Pediatric HIV-1 infection: advances and  
23 remaining challenges. *AIDS Rev* 4:21-6.
- 24 30. Mascola, J. R., P. D'Souza, P. Gilbert, B. H. Hahn, N. L. Haigwood, L. Morris, C. J.  
25 Petropoulos, V. R. Polonis, M. Sarzotti, and D. C. Montefiori. 2005.  
26 Recommendations for the design and use of standard virus panels to assess  
27 neutralizing antibody responses elicited by candidate human immunodeficiency  
28 virus type 1 vaccines. *J Virol* 79:10103-7.
- 29 31. Mattapallil, J. J., Z. Smit-McBride, M. McChesney, and S. Dandekar. 1998.  
30 Intestinal intraepithelial lymphocytes are primed for gamma interferon and MIP-  
31 1beta expression and display antiviral cytotoxic activity despite severe CD4(+) T-cell  
32 depletion in primary simian immunodeficiency virus infection. *J Virol* 72:6421-9.
- 33 32. Mc Cann, C. M., R. J. Song, and R. M. Ruprecht. 2005. Antibodies: can they protect  
34 against HIV infection? *Curr Drug Targets Infect Disord* 5:95-111.
- 35 33. McClure, H. M., D. C. Anderson, A. A. Ansari, P. N. Fultz, S. A. Klumpp, and R. F.  
36 Schinazi. 1990. Nonhuman primate models for evaluation of AIDS therapy. *Ann N*  
37 *Y Acad Sci* 616:287-98.
- 38 34. Michael, N. L., A. E. Brown, R. F. Voigt, S. S. Frankel, J. R. Mascola, K. S.  
39 Brothers, M. Louder, D. L. Birx, and S. A. Cassol. 1997. Rapid disease progression  
40 without seroconversion following primary human immunodeficiency virus type 1  
41 infection--evidence for highly susceptible human hosts. *J Infect Dis* 175:1352-9.
- 42 35. Montagnier, L., C. Brenner, S. Chamaret, D. Guetard, A. Blanchard, J. de Saint  
43 Martin, J. D. Poveda, G. Pialoux, and M. L. Gougeon. 1997. Human  
44 immunodeficiency virus infection and AIDS in a person with negative serology. *J*  
45 *Infect Dis* 175:955-9.

- 1 36. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Ruker,  
2 and H. Katinger. 1993. A conserved neutralizing epitope on gp41 of human  
3 immunodeficiency virus type 1. *J Virol* 67:6642-7.
- 4 37. Ndung'u, T., Y. Lu, B. Renjifo, N. Touzjian, N. Kushner, V. Pena-Cruz, V. A.  
5 Novitsky, T. H. Lee, and M. Essex. 2001. Infectious simian/human  
6 immunodeficiency virus with human immunodeficiency virus type 1 subtype C from  
7 an African isolate: rhesus macaque model. *J Virol* 75:11417-25.
- 8 38. Newell, M. L. 2006. Current issues in the prevention of mother-to-child transmission  
9 of HIV-1 infection. *Trans R Soc Trop Med Hyg* 100:1-5.
- 10 39. Nishimura, Y., C. R. Brown, J. J. Mattapallil, T. Igarashi, A. Buckler-White, B. A.  
11 Lafont, V. M. Hirsch, M. Roederer, and M. A. Martin. 2005. Resting naive CD4+ T  
12 cells are massively infected and eliminated by X4-tropic simian-human  
13 immunodeficiency viruses in macaques. *Proc Natl Acad Sci U S A* 102:8000-5.
- 14 40. Pahar, B., X. Wang, J. Dufour, A. A. Lackner, and R. S. Veazey. 2007. Virus-  
15 specific T cell responses in macaques acutely infected with SHIV(sf162p3). *Virology*  
16 363:36-47.
- 17 41. Parker, C. E., L. J. Deterding, C. Hager-Braun, J. M. Binley, N. Schulke, H.  
18 Katinger, J. P. Moore, and K. B. Tomer. 2001. Fine definition of the epitope on the  
19 gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing  
20 monoclonal antibody 2F5. *J Virol* 75:10906-11.
- 21 42. Pinto, A. N. 1996. AIDS and cerebrovascular disease. *Stroke* 27:538-43.
- 22 43. Raghavan, R., E. B. Stephens, S. V. Joag, I. Adany, D. M. Pinson, Z. Li, F. Jia, M.  
23 Sahni, C. Wang, K. Leung, L. Foresman, and O. Narayan. 1997. Neuropathogenesis  
24 of chimeric simian/human immunodeficiency virus infection in pig-tailed and rhesus  
25 macaques. *Brain Pathol* 7:851-61.
- 26 44. Rasmussen, R. A., H. Ong, R. Song, A. L. Chenine, M. Ayash-Rashkovsky, S. L. Hu,  
27 P. Polacino, J. G. Else, F. J. Novembre, and R. M. Ruprecht. 2007. Efficacy of a  
28 multigenic protein vaccine containing multimeric HIV gp160 against heterologous  
29 SHIV clade C challenges. *Aids* 21:1841-8.
- 30 45. Reimann, K. A., J. T. Li, R. Veazey, M. Halloran, I. W. Park, G. B. Karlsson, J.  
31 Sodroski, and N. L. Letvin. 1996. A chimeric simian/human immunodeficiency virus  
32 expressing a primary patient human immunodeficiency virus type 1 isolate env  
33 causes an AIDS-like disease after in vivo passage in rhesus monkeys. *J Virol*  
34 70:6922-8.
- 35 46. Rouet, F., C. Sakarovitch, P. Msellati, N. Elenga, C. Montcho, I. Viho, S. Blanche, C.  
36 Rouzioux, F. Dabis, and V. Leroy. 2003. Pediatric viral human immunodeficiency  
37 virus type 1 RNA levels, timing of infection, and disease progression in African  
38 HIV-1-infected children. *Pediatrics* 112:e289.
- 39 47. Sanders, R. W., M. Venturi, L. Schiffner, R. Kalyanaraman, H. Katinger, K. O.  
40 Lloyd, P. D. Kwong, and J. P. Moore. 2002. The mannose-dependent epitope for  
41 neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein  
42 gp120. *J Virol* 76:7293-305.
- 43 48. Scanlan, C. N., R. Pantophlet, M. R. Wormald, E. Ollmann Saphire, R. Stanfield, I.  
44 A. Wilson, H. Katinger, R. A. Dwek, P. M. Rudd, and D. R. Burton. 2002. The  
45 broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12

- 1 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. *J*  
2 *Virol* 76:7306-21.
- 3 49. Seaman, M. S., L. Xu, K. Beaudry, K. L. Martin, M. H. Beddall, A. Miura, A.  
4 Sambor, B. K. Chakrabarti, Y. Huang, R. Bailer, R. A. Koup, J. R. Mascola, G. J.  
5 Nabel, and N. L. Letvin. 2005. Multiclade human immunodeficiency virus type 1  
6 envelope immunogens elicit broad cellular and humoral immunity in rhesus  
7 monkeys. *J Virol* 79:2956-63.
- 8 50. Siddappa, N. B., P. K. Dash, A. Mahadevan, N. Jayasuryan, F. Hu, B. Dice, R.  
9 Keefe, K. S. Satish, B. Satish, K. Sreekanthan, R. Chatterjee, K. Venu, P.  
10 Satishchandra, V. Ravi, S. K. Shankar, R. Shankarappa, and U. Ranga. 2004.  
11 Identification of subtype C human immunodeficiency virus type 1 by subtype-  
12 specific PCR and its use in the characterization of viruses circulating in the  
13 southern parts of India. *J Clin Microbiol* 42:2742-51.
- 14 51. Song, R. J., A. L. Chenine, R. A. Rasmussen, C. R. Ruprecht, S. Mirshahidi, R. D.  
15 Grisson, W. Xu, J. B. Whitney, L. M. Goins, H. Ong, P. L. Li, E. Shai-Kobiler, T.  
16 Wang, C. M. McCann, H. Zhang, C. Wood, C. Kankasa, W. E. Secor, H. M.  
17 McClure, E. Strobert, J. G. Else, and R. M. Ruprecht. 2006. Molecularly cloned  
18 SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5  
19 simian-human immunodeficiency virus encoding HIV clade C Env. *J Virol* 80:8729-  
20 38.
- 21 52. Stambas, J., S. A. Brown, A. Gutierrez, R. Sealy, W. Yue, B. Jones, T. D. Lockey, A.  
22 Zirkel, P. Freiden, B. Brown, S. Surman, C. Coleclough, K. S. Slobod, P. C.  
23 Doherty, and J. L. Hurwitz. 2005. Long lived multi-isotype anti-HIV antibody  
24 responses following a prime-double boost immunization strategy. *Vaccine* 23:2454-  
25 64.
- 26 53. Stephens, E. B., S. Mukherjee, M. Sahni, W. Zhuge, R. Raghavan, D. K. Singh, K.  
27 Leung, B. Atkinson, Z. Li, S. V. Joag, Z. Q. Liu, and O. Narayan. 1997. A cell-free  
28 stock of simian-human immunodeficiency virus that causes AIDS in pig-tailed  
29 macaques has a limited number of amino acid substitutions in both SIVmac and  
30 HIV-1 regions of the genome and has offered cytotropism. *Virology* 231:313-21.
- 31 54. Stiegler, G., R. Kunert, M. Purtscher, S. Wolbank, R. Voglauer, F. Steindl, and H.  
32 Katinger. 2001. A potent cross-clade neutralizing human monoclonal antibody  
33 against a novel epitope on gp41 of human immunodeficiency virus type 1. *AIDS Res*  
34 *Hum Retroviruses* 17:1757-65.
- 35 55. Thompson, J. D., T. J. Gibson, F. Plewniak, F. Jeanmougin, and D. G. Higgins.  
36 1997. The CLUSTAL\_X windows interface: flexible strategies for multiple sequence  
37 alignment aided by quality analysis tools. *Nucleic Acids Res* 25:4876-82.
- 38 56. Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, K.  
39 Srinivasan, J. Sodroski, J. P. Moore, and H. Katinger. 1996. Human monoclonal  
40 antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein  
41 of human immunodeficiency virus type 1. *J Virol* 70:1100-8.
- 42 57. Veazey, R. S., M. DeMaria, L. V. Chalifoux, D. E. Shvetz, D. R. Pauley, H. L.  
43 Knight, M. Rosenzweig, R. P. Johnson, R. C. Desrosiers, and A. A. Lackner. 1998.  
44 Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication  
45 in SIV infection. *Science* 280:427-31.

- 1 58. Velu, V., S. Kannanganat, C. Ibegbu, L. Chennareddi, F. Villinger, G. J. Freeman,  
2 R. Ahmed, and R. R. Amara. 2007. Elevated expression levels of inhibitory receptor  
3 programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during  
4 chronic infection but not after vaccination. *J Virol* 81:5819-28.
- 5 59. Vlasak, J., and R. M. Ruprecht. 2006. AIDS vaccine development and challenge  
6 viruses: getting real. *Aids* 20:2135-40.
- 7 60. Wu, Y., K. Hong, A. L. Chenine, J. B. Whitney, W. Xu, Q. Chen, Y. Geng, R. M.  
8 Ruprecht, and Y. Shao. 2005. Molecular cloning and in vitro evaluation of an  
9 infectious simian-human immunodeficiency virus containing env of a primary  
10 Chinese HIV-1 subtype C isolate. *J Med Primatol* 34:101-7.
- 11 61. Zhang, H., F. Hoffmann, J. He, X. He, C. Kankasa, R. Ruprecht, J. T. West, G. Orti,  
12 and C. Wood. 2005. Evolution of subtype C HIV-1 Env in a slowly progressing  
13 Zambian infant. *Retrovirology* 2:67.
- 14 62. Zhang, H., F. Hoffmann, J. He, X. He, C. Kankasa, J. T. West, C. D. Mitchell, R. M.  
15 Ruprecht, G. Orti, and C. Wood. 2006. Characterization of HIV-1 subtype C  
16 envelope glycoproteins from perinatally infected children with different courses of  
17 disease. *Retrovirology* 3:73.
- 18 63. Zhou, T., L. Xu, B. Dey, A. J. Hessel, D. Van Ryk, S. H. Xiang, X. Yang, M. Y.  
19 Zhang, M. B. Zwick, J. Arthos, D. R. Burton, D. S. Dimitrov, J. Sodroski, R. Wyatt,  
20 G. J. Nabel, and P. D. Kwong. 2007. Structural definition of a conserved  
21 neutralization epitope on HIV-1 gp120. *Nature* 445:732-7.
- 22 64. Zwick, M. B., R. Jensen, S. Church, M. Wang, G. Stiegler, R. Kunert, H. Katinger,  
23 and D. R. Burton. 2005. Anti-human immunodeficiency virus type 1 (HIV-1)  
24 antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-  
25 proximal external region of glycoprotein gp41 to neutralize HIV-1. *J Virol* 79:1252-  
26 61.
- 27 65. Zwick, M. B., A. F. Labrijn, M. Wang, C. Spenlehauer, E. O. Saphire, J. M. Binley,  
28 J. P. Moore, G. Stiegler, H. Katinger, D. R. Burton, and P. W. Parren. 2001.  
29 Broadly neutralizing antibodies targeted to the membrane-proximal external region  
30 of human immunodeficiency virus type 1 glycoprotein gp41. *J Virol* 75:10892-905.  
31  
32

1 **Figure legends**

2 FIG. 1. Construction of SHIV-2873Ni. (A) Identification of an infectious *env* clone. Primary  
3 full-length *env* genes were PCR amplified from genomic DNA of normal human donor PBMC  
4 cocultured with infected PBMC of Zambian infant 2873i collected at 2 months of age and cloned  
5 into the expression vector pcDNA6/B. Infant 2873i was a rapid progressor who died of AIDS-  
6 related disease within 1 year of birth to an HIV-C-positive mother. To identify an infectious  
7 envelope, the resultant constructs were cotransfected into 293T cells with HIV-1 ΔEN, an  
8 infectious HIV provirus deleted in *env* and *nef* and encoding GFP in lieu of *nef*. The resulting  
9 pseudovirus released into cell supernatants was used to infect CEM.NKR.CCR5 cells, which  
10 were screened for GFP expression. HIV-1 ΔEN cotransfected with ADA *env* was used as  
11 positive control. (B) Construction of SHIV-2873Nip. SHIV-1157ipd3N4 (51) was used as  
12 backbone. The 2.2 kb KpnI (K) - BamHI (B) fragment of HIV2873i (spanning most of gp120,  
13 the entire gp41 extracellular domain, the transmembrane region (TM), and part of the  
14 cytoplasmic domain) was amplified to replace the corresponding region of the proviral  
15 backbone. The modified 3'-half was ligated with the 5' half of SHIV-vpu<sup>+</sup> proviral DNA to  
16 form full-length SHIV-2873Ni. NN, 2 NF-κB sites are present in the 3'LTR; during viral  
17 replication, this duplication is copied into the 5'LTR also.

18  
19 FIG. 2. Coreceptor usage of SHIV-2873i, SHIV-2873Ni and SHIV-2873Nip. U87.CD4.CCR5  
20 cells and U87.CD4.CXCR4 were exposed to SHIV-2873Ni, SHIV-2873Nip, SHIV<sub>SF162</sub> (HIV  
21 clade B *env*, R5), and SHIV-vpu<sup>+</sup> (HIV clade B *env*, X4). The levels of p27 Gag were measured  
22 in the supernatants as indicated. SHIV-2873i contains the standard SIVmac239 LTRs with only  
23 a single NF-κB site/LTR; it was built using SHIV-vpu<sup>+</sup> as backbone.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12

FIG. 3. Serial passage of SHIV-2873Ni in rhesus macaques. (A) SHIV-2873Ni was passaged in five Indian-origin RM through serial blood transfer. Animal RWa-9 had been exposed previously to SHIV-2873Ni but had remained uninfected. After receiving blood from donor RAi-8, RM RWa-9 and all monkeys shown in Fig. 2A became infected. (B) Viral loads were measured after serial passage at the time points indicated. †, monkey RNt-9 developed fatal cerebral hemorrhages due to severe thrombocytopenia at week 92 post-inoculation. (C and D) absolute CD4<sup>+</sup> T-cell numbers, platelet counts and CD4<sup>+</sup>CD29<sup>+</sup> memory T cells were assessed during the course of the infection. The dashed line denotes the lowest normal value (10%) for the CD4<sup>+</sup>CD29<sup>+</sup> T cells.

ACCEPTED

1 FIG. 4. Phylogenetic tree showing the relationship between SHIV-2873Ni and SHIV-2873Nip  
2 Env sequences and those of other primary strains of HIV. Phylogenetic trees were constructed  
3 from full-length Env sequences by using the Neighbor-joining method. Major subtypes of HIV  
4 group M were used as reference sequences; sequences from SHIV-1157i, SHIV-1157ip, SHIV-  
5 1157ipd3N4 (51) and HIV1084i (14) were also included, since HIV1084i and the *env* genes in  
6 these SHIVs had been derived from the same cohort of infected mothers and their infants in  
7 Lusaka, Zambia. The scale bar indicates the genetic distance along the horizontal branches, and  
8 the numbers at the nodes are bootstrap values. B. Evolution of SHIV-2873Nip Env during  
9 passage and replication in monkey RNT-9. The deletions of 5 and 3 aa at the end and beginning  
10 of V4 and V5 domains of gp120, respectively, in the adapted SHIV-2873Nip are shown. The  
11 Env consensus sequence for SHIV-2873Nip was derived by sequencing 8 individual clones  
12 encoding infectious *env* genes.

13  
14  
15 FIG. 5. Oral and intrarectal inoculation of SHIV-2873Nip. Two monkeys (RBg-10 and RUF-10)  
16 were inoculated orally or intrarectally, respectively, with SHIV-2873Nip stock. (B) Six monkeys  
17 were used in a repeated low-dose i.r. titration; the aim was to find a virus dose leading to  
18 systemic infection (defined as viral RNA  $\geq 10^4$  copies/ml) after a maximum of five weekly i.r.  
19 inoculations. Monkeys remaining uninfected at week 2 after the 5<sup>th</sup> weekly low-dose virus  
20 challenge were given a single high-dose SHIV-2873Nip dose (30,000 TCID<sub>50</sub>). Viral loads were  
21 measured at the time points indicated. The horizontal dotted line indicates lower limit of  
22 detection (<50 viral RNA copies/ml). (C and D) Estimation of CD4<sup>+</sup> T-cell loss in blood and gut:  
23 comparison of CD4<sup>+</sup> T cells in rectal biopsy specimens (collected between weeks 6 and 12 after  
24 the last, successful inoculation) and blood of RM inoculated with SHIV-2873Nip compared with

1 uninfected controls. The asterisk (\*) in panel C designates the percent CD4<sup>+</sup> T cells in rectal  
2 mucosa of monkey RNt-9 collected at week 84 post-inoculation.  
3

ACCEPTED

TABLE 1. Neutralization of clade C SHIV strains in human and rhesus monkey PBMC

Source of Abs (human nmAb or RM name)	IC <sub>50</sub> (μg/ml or 1/x dilution)					
	SHIV-2873Ni*		SHIV-2873Nip*		SHIV-1157ipd3N4*	
	Human PBMC	RM PBMC	Human PBMC	RM PBMC	Human PBMC	RM PBMC
Human nmAbs						
IgG1b12	0.36	ND	0.4	0.03	1.3	0.48
2G12	>40	ND	>40	>40	>40	>40
2F5	0.32	ND	0.3	0.18	0.67	2.0
4E10	0.035	ND	0.035	0.05	0.15	0.43
4x	0.40	ND	0.09	0.05	0.15	0.19
Polyclonal RM plasma/sera						
autologous plasma:						
RNt-9 (time of virus isolation)	ND	ND	662	ND	ND	ND
RNt-9 (10 mos post virus isolation)	ND	ND	1,036	ND	ND	ND
heterologous sera:						
RHy-9 (SHIV-1157ipd3N4-infected RM) <sup>†</sup>	ND	ND	3,722	ND	>10,240	ND
RJa-9 (SHIV-1157ip-infected RM)	ND	ND	2,048	ND	>10,240	ND

\*All three viruses lack the 2G12 epitope; 4x, quadruple combination of IgG1b12, 2G12, 2F5 and 4E10 at a 1:1:1:1 ratio. ND, not determined; <sup>†</sup>, RHy-9 was described by Rasmussen et al. (44); RM, rhesus monkey.

TABLE 2. Sensitivity of R5 SHIV strains to soluble CD4, human nmAbs and serum samples

SHIV strain	IC <sub>50</sub> (μg/ml) in TZM-bl cells <sup>1</sup>							IC <sub>50</sub> (reciprocal serum dilution) in TZM-bl cells <sup>1</sup>							Tier
	clade	sCD4	IgG1 b12	2G12	2F5	4E10	HIVIG	BB7	BB55	BB68	BB75	BB80	BB81	BB87	
SHIV-2873Nip (Zambian env; early isolate)	C	0.1	0.5	>25	>25	>25	16.8	340	876	509	716	1,273	157	876	1
SHIV-1157ipd3N4 (Zambian env; late isolate)	C	0.4	7.0	>25	>25	>25	1,160	105	131	86	79	72	47	260	2
SHIV <sub>SF162P4</sub>	B	<0.01	15.7	15.7	1.5	0.7	25	363	2,543	328	615	828	211	360	1
SHIV <sub>SF162P3</sub>	B	6.0	>25	>25	>25	>25	1,505	24	65	22	27	25	<20	180	2

Spectrum of neutralization sensitivity of R5 SHIV strains encoding HIV clade B or C *env*. <sup>1</sup>Values represent the concentration (μg/ml for soluble CD4 (sCD4) and human nmAbs IgG1b12, 2G12, 2F5, 4E10, or HIVIG) or the dilution (for serum samples) at which relative luciferase units (RLU) were reduced 50% compared to virus control wells. BB47, BB55, BB68, BB75, BB80, BB81, and BB87 are serum samples from individuals infected with HIV-1 clade C. HIVIG, polyclonal high-titer anti-HIV Ig preparation.

Downloaded from jvi.asm.org at UNIV OF NEBRASKA LINCOLN on November 21, 2018

Fig. 1




Fig. 2




Fig. 3







Fig. 4



**B**

		V4
SHIV-2873Ni	EFFYCNTSSLFNHIYNSSGRDPYNV	SHSNASET
SHIV-2873Nip	.....EK.....	-----
		V5
SHIV-2873Ni	PIAGDITCTSNITGLLLTRDGGM	NSNTEENSTQ
SHIV-2873Nip	.....	-----

Fig. 5

